{
  "id": "64041f38201352f04a00001f",
  "type": "yesno",
  "question": "Is tebentafusp effective for uveal melanoma?",
  "ideal_answer": "Yes. Tebentafusp effective for uveal melanoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34999237",
    "http://www.ncbi.nlm.nih.gov/pubmed/35364557",
    "http://www.ncbi.nlm.nih.gov/pubmed/35364798"
  ],
  "snippets": [
    {
      "text": "Tebentafusp (tebentafusp-tebn; Kimmtrak\u00ae) is a first-in-class, bispecific gp100 peptide-HLA-A*02:01 directed T cell receptor (TCR) CD3 T cell engager being developed by Immunocore for the treatment of uveal melanoma and malignant melanoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35364798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35364798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tebentafusp was granted full approval on January 25th 2022 in the setting of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35364557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In a large meta-analysis, surgical treatment was associated with 6 months longer median overall survival as compared to conventional chemotherapy and, recently, tebentafusp as first-line treatment at the first interim analysis of a randomized phase III trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab; these treatments currently apply to selected patients. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34999237",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}